Correlation Between Zentalis Pharmaceuticals and Neurocrine Biosciences

Can any of the company-specific risk be diversified away by investing in both Zentalis Pharmaceuticals and Neurocrine Biosciences at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Zentalis Pharmaceuticals and Neurocrine Biosciences into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Zentalis Pharmaceuticals Llc and Neurocrine Biosciences, you can compare the effects of market volatilities on Zentalis Pharmaceuticals and Neurocrine Biosciences and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Zentalis Pharmaceuticals with a short position of Neurocrine Biosciences. Check out your portfolio center. Please also check ongoing floating volatility patterns of Zentalis Pharmaceuticals and Neurocrine Biosciences.

Diversification Opportunities for Zentalis Pharmaceuticals and Neurocrine Biosciences

0.3

Correlation Coefficient

Zentalis Pharmaceuticals  Neurocrine Biosciences

Weak diversification

The 3 months correlation between Zentalis and Neurocrine is 0.3. Overlapping area represents the amount of risk that can be diversified away by holding Zentalis Pharmaceuticals Llc and Neurocrine Biosciences in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Neurocrine Biosciences and Zentalis Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Zentalis Pharmaceuticals Llc are associated (or correlated) with Neurocrine Biosciences. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Neurocrine Biosciences has no effect on the direction of Zentalis Pharmaceuticals i.e., Zentalis Pharmaceuticals and Neurocrine Biosciences go up and down completely randomly.

Pair Corralation between Zentalis Pharmaceuticals and Neurocrine Biosciences

Given the investment horizon of 90 days Zentalis Pharmaceuticals Llc is expected to under-perform the Neurocrine Biosciences. In addition to that, Zentalis Pharmaceuticals is 3.46 times more volatile than Neurocrine Biosciences. It trades about -0.05 of its total potential returns per unit of risk. Neurocrine Biosciences is currently generating about 0.04 per unit of volatility. If you would invest  12,231  in Neurocrine Biosciences on September 17, 2024 and sell it today you would earn a total of  439.00  from holding Neurocrine Biosciences or generate 3.59% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Zentalis Pharmaceuticals Llc  vs.  Neurocrine Biosciences

Zentalis Pharmaceuticals

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Zentalis Pharmaceuticals Llc has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain quite persistent which may send shares a bit higher in January 2025. The latest mess may also be a sign of long-standing up-swing for the company institutional investors.

Neurocrine Biosciences

Risk-Adjusted Performance

3 of 100

Insignificant

Compared to the overall equity markets, risk-adjusted returns on investments in Neurocrine Biosciences are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of fairly strong forward indicators, Neurocrine Biosciences is not utilizing all of its potentials. The recent stock price disturbance, may contribute to short-term losses for the investors.

Pair Trading with Zentalis Pharmaceuticals and Neurocrine Biosciences

The main advantage of trading using opposite Zentalis Pharmaceuticals and Neurocrine Biosciences positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Zentalis Pharmaceuticals position performs unexpectedly, Neurocrine Biosciences can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Neurocrine Biosciences will offset losses from the drop in Neurocrine Biosciences' long position.

The idea behind Zentalis Pharmaceuticals Llc and Neurocrine Biosciences pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Stocks Directory module to find actively traded stocks across global markets.